ATyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ATyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor's section of the company's website at . Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA.
圣地亚哥，2024年12月17日（环球新闻网）-- aTyr Pharma, Inc.（纳斯达克：ATYR），一家处于临床阶段的生物技术公司，致力于从其专有的tRNA合成酶平台进行首创药物的发现和开发，今天宣布，总裁兼首席执行官Sanjay S. Shukla万.D.万.S.将在定于2025年1月13日至16日在加利福尼亚州旧金山举行的第43届J.P.摩根医疗保健大会上进行演讲。
Details of the presentation appear below:
演讲的详细信息如下：
Conference: 43rd Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 16, 2025
Time: 8:15am PST
Location: San Francisco, CA
Format: Corporate Presentation
会议：第43届J.P.摩根医疗保健大会
日期：2025年1月16日，星期四
时间：太平洋标准时间上午8:15
地点：加州旧金山
格式：公司演示
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor's section of the company's website at . Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.
除了演示，公司管理层将会参与与注册会议的投资者进行一对一的会议。演示的网络直播将在公司网站的投资者部分提供。活动后，演示的重播将在aTyr网站上提供至少30天。如需更多信息，请联系 investorrelations@atyrpharma.com。
About aTyr
关于aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit .
aTyr是一家处于临床阶段的生物技术公司，利用进化智能将tRNA合成酶生物学转化为治疗纤维化和炎症的新疗法。tRNA合成酶是古老且必不可少的蛋白质，已经进化出独特的结构域，调节人类多种细胞外通路。aTyr的发现平台专注于通过揭示由其专有的20种tRNA合成酶衍生的结构域驱动的信号通路来解锁隐藏的治疗干预点。aTyr的主要治疗候选药物是efzofitimod，一种首创生物免疫调节剂，正在开发用于治疗间质性肺病，这是一组可以导致炎症和肺部渐进性纤维化或瘢痕的免疫介导疾病。如需更多信息，请访问。
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
联系：
Ashlee Dunston
董事，投资者关系和公共事务
adunston@atyrpharma.com
